JonesTrading analyst Justin Walsh has reiterated their bullish stance on CATX stock, giving a Buy rating today.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Justin Walsh has given his Buy rating due to a combination of factors that highlight the potential of Perspective Therapeutics. Despite the current share price weakness, Walsh sees this as an opportunity to invest, largely due to the promising prospects of the company’s Pb-212-based clinical pipeline and technology platform. The anticipation of a data-rich 2026 further strengthens this outlook, as the company is expected to deliver significant clinical updates and efficacy data from its programs.
Additionally, Walsh identifies Perspective Therapeutics as a potential acquisition target, given the interest from major pharmaceutical companies in radiopharmaceutical pipelines. Although the early efficacy signals for the lead asset Pb-212-VMT-α-NET have lagged behind competitors, the ongoing dose escalation and safety profile offer a competitive edge. The company’s strong cash position, which is expected to sustain operations into late 2026, also supports the Buy rating, indicating financial stability and capacity for continued development.
Walsh covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Achieve Life Sciences, and Alto Neuroscience, Inc.. According to TipRanks, Walsh has an average return of 17.8% and a 36.33% success rate on recommended stocks.
In another report released today, BTIG also reiterated a Buy rating on the stock with a $14.00 price target.